Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford hosts industry event on cancer precision prevention trials

Professor Sarah Blagden led a panel discussion focused on the opportunities of cancer precision prevention.

Featured interview with GambitBio CEO and OxCODE researcher

GambitBio is developing an at-home lateral flow test to screen for the most common cancers, empowering people to take control of their health and reduce the number of cancer-related deaths. Cancer Research Horizons recently interviewed CEO, Tiffany Ma, who co-founded the venture while completing her DPhil at the University of Oxford.

OxCODE researchers at the inaugural Cancer Prevention Research conference 2024

Over 20 Oxford researchers engaged with over 350 attendees from all over the world at a truly interdisciplinary cancer prevention conference.

OxCODE travel awards 2024

Congratulations to Jingfei Cheng, Holly Eggington, Yi-Jhih Huang, Zhe Huang and Joshua Moore who have been awarded OxCODE funds to attend this year’s major cancer prevention and early detection conferences.

Highlights from CRUK’s Early Diagnosis Conference 2024

OxCODE primary care researchers recently attended this year's Cancer Research UK Early Diagnosis Conference in Birmingham, which focused on the theme 'Driving Evidence into Practice'.

Blood proteins may be able to predict risk of cancer more than seven years before it is diagnosed

Proteins linked to cancer can start appearing in people’s blood more than seven years before they’re diagnosed. In the future, it’s possible doctors could use these early warning signs to find and treat cancer much earlier than they’re able to today.

Researchers develop new way to identify people with new-onset diabetes who are at risk of pancreatic cancer

The new method could help people with new-onset diabetes at high-risk of developing pancreatic cancer to be identified more accurately so that they can be monitored.

Oxford lung cancer early detection trial reaches 400 participants

The SCOOT study seeks current and former smokers across England to provide blood samples for ongoing research aiming to improve lung cancer diagnosis.

£1.7 million for vaccine to prevent lung cancer

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

Funding to compare imaging modalities for liver cancer detection

The DeLIVER team will evaluate non-contrast-enhanced MRI and compare it to standard of care ultrasound in a cohort of patients under surveillance for liver cancer.

Ultrasensitive detection of p53 cancer biomarker

Professor Jason Davis and team have developed a new sensor to selectively and quantitatively measure p53 autoantibodies in the blood, levels of which are raised in a broad range of cancers.

Crowd-sourcing approach assesses current methods for improved automated detection and boundary mapping of colorectal cancer precursors

A computer vision challenge was set to objectively quantify the generalisability of polyp detection and mapping algorithms, and challenge participants to innovate novel methods.

First patient recruited to MILI trial

Oxford’s first precision prevention cancer trial in people with Li Fraumeni Syndrome has opened to recruitment

Challenges for colorectal cancer risk stratification in people with IBD using histology

A team of pathologists were unable to validate a histology-based assessment of cancer risk in people with inflammatory bowel disease (IBD).

Oxford Centre for Early Cancer Detection Symposium 2023 – a recap

On Tuesday 5th December, the Oxford early cancer detection community gathered at the Mathematical Institute in Oxford to hear some highlights from OxCODE’s research in the past year and to discuss ideas for future projects.

Oxford Cancer Precision Prevention Symposium – a recap

To celebrate the launch of the UK’s first CRUK clinical trials unit dedicated to cancer precision prevention in Oxford, we held a research symposium that highlighted the spectra of Cancer Precision Prevention clinical programmes across the UK.

University of Oxford Awarded £3 Million to Establish HealthTech Research Centre

The Nuffield Department of Primary Care Health Sciences wins an NIHR award for a new HealthTech Research Centre (HRC) to explore innovative Health Technology to enhance community and primary care.

OxCODE researchers at the Early Detection of Cancer Conference 2023

Oxford’s early detection research was featured at this annual event.

First private specialised haematology clinic and laboratory in sub-Saharan Africa launched

SerenOx Africa, led by Professor Anna Schuh, aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility also aims to provide early cancer detection for high-risk patients.

Collaboration announced to develop the use of AI to evaluate Barrett’s oesophagus

An agreement between Satisfai Health Inc and the University of Oxford will progress the automated assessment of Barrett’s oesophagus with the aim of determining patients most at risk of developing oesophageal cancer.

Load More